Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4–dependent mechanism

Marcus D. Säemann,1 Thomas Weichhart,2 Maximilian Zeyda,3 Günter Staffler,2 Michael Schunn,2 Karl M. Stuhlmeier,4 Yuri Sobanov,6 Thomas M. Stulnig,3,4 Shizuo Akira,7 Alexander von Gabain,2 Uwe von Ahsen,2 Walter H. Hörl,1 and Gerhard J. Zlabinger5

1Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University Vienna, Vienna, Austria. 2Intercell AG, Vienna, Austria. 3Department of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Medical University Vienna, Vienna, Austria. 4Ludwig Boltzmann Institute for Rheumatology, Vienna, Austria. 5Institute of Immunology, Medical University Vienna, Vienna, Austria. 6Center of Molecular Medicine (CeMM), Austrian Academy of Sciences, Clinical Division of Endocrinology and Metabolism, Medical University Vienna, Vienna, Austria. 7Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Tamm-Horsfall glycoprotein (THP) is expressed exclusively in the kidney and constitutes the most abundant protein in mammalian urine. A critical role for THP in antibacterial host defense and inflammatory disorders of the urogenital tract has been suggested. We demonstrate that THP activates myeloid DCs via Toll-like receptor-4 (TLR4) to acquire a fully mature DC phenotype. THP triggers typical TLR signaling, culminating in activation of NF-κB. Bone marrow–derived macrophages from TLR4- and MyD88-deficient mice were nonresponsive to THP in contrast to those from TLR2- and TLR9-deficient mice. In vivo THP-driven TNF-α production was evident in WT but not in Tlr4–/– mice. Importantly, generation of THP-specific Abs consistently detectable in urinary tract inflammation was completely blunted in Tlr4–/– mice. These data show that THP is a regulatory factor of innate and adaptive immunity and therefore could have significant impact on host immunity in the urinary tract.

Introduction

Professional APCs, such as DCs, are pivotally positioned at the interface of innate and adaptive immunity (1). Recognition of pathogens leads to a typical maturation program including upregulation of costimulatory and MHC molecules, migration of DCs to adjacent lymph nodes, and subsequent priming of naive antigen-specific T cells. For pathogen recognition, DCs are specifically equipped with distinct pattern recognition receptors such as Toll-like receptors (TLRs) to detect pathogen-associated molecular patterns (2, 3). Microbial components recognized by TLR have been identified for TLR2 (e.g., peptidoglycan), TLR3 (e.g., double-stranded RNA), TLR4 (e.g., LPS), TLR5 (bacterial flagellin), TLR6 (e.g., mycoplasmal macrophage-activating lipopeptide 2 kDa), TLR9 (e.g., unmethylated bacterial CpG DNA), and TLR11 (uropathogenic bacteria) (4, 5). Moreover, various conserved sugar residues have been shown to be involved in accessory cell stimulation in concert with TLR-dependent cellular activation by putative lectin-binding receptors (6–8). Recently, distinct host-derived molecules such as fibronectin, hyaluronic acid, or β-defensin 2 have also been shown to signal through TLR (9–11). Hence, TLRs are thought to essentially contribute to transduce signals by exogenous as well as endogenous molecules to activate distinct immune cells or to control tissue integrity, respectively (12).

Nonstandard abbreviations used: EMSA, electromobility shift assay; HUVEC, human umbilical vein endothelial cell; IRAK-1, IL-1 receptor–associated kinase 1; MLC, mixed lymphocyte culture; rh, recombinant human; TF, tissue factor; TLR, Toll-like receptor; THP, Tamm-Horsfall glycoprotein; TLR, Toll-like receptor.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 115:468–475 (2005). doi:10.1172/JCI200522720.
that LPS contamination of the THP preparation had caused immune cell stimulation, we first tested for their endotoxin content the materials used for DC culturing and found them to be endotoxin free (<0.06 U/ml) as confirmed by Limulus amebocyte lysate assay (data not shown). Furthermore, we preincubated the THP probe with polymyxin B, a specific inhibitor for LPS, before adding it to immature DCs. DC maturation induced by THP was independent of LPS, since polymyxin B did not affect THP-induced DC maturation but completely prevented activation by LPS (Figure 2A). Similarly, absorption over a polymyxin B column, which effectively eliminates LPS, did not affect TNF-α production induced by the THP preparation but abolished the response to LPS (Figure 2B). Conversely, proteinase K treatment did not inhibit LPS-induced TNF-α production but restrained activation by THP.

Furthermore, we sought to determine a potential functional effect of possible LPS contamination in the THP preparation. Recent data demonstrated that THP, in contrast to LPS, is not able to stimulate the expression of tissue factor (TF) in human umbilical vein endothelial cells (HUVECs) (18). LPS induced TF expression in HUVECs, whereas THP was not able to induce TF in endothelial cells even in IFN-γ-pretreated cells that are highly sensitive to LPS (Figure 2C). These results suggest a functional difference in LPS and THP signaling. Collectively, these experiments rule out the possibility that the effects of THP on DCs are due to contamination with LPS. To exclude contaminating molecules other than LPS, the standard THP preparation obtained by repeated NaCl precipitation from urine was further purified by 2 sequential procedures taking advantage of the fact that THP forms a gel when monovalent ions above 60 mmol/l are present. After induction of gel formation by 70 mM sodium phosphate, THP was purified by ultracentrifugation (23). The pellet fraction containing THP was fully active on C57BL/6 splenocytes and the murine macrophage cell line RAW264.7 and IL-6 production (Figure 2D and data not shown). Moreover, the ultracentrifuged THP was further purified over a diatomaceous earth filter, which is known to purify THP to homogeneity (24). This THP preparation obtained by repeated NaCl precipitation from urine was further purified by 2 sequential procedures taking advantage of the fact that THP forms a gel when monovalent ions above 60 mmol/l are present. After induction of gel formation by 70 mM sodium phosphate, THP was purified by ultracentrifugation (23). The pellet fraction containing THP was fully active on C57BL/6 splenocytes.

Figure 1
THP activates professional APCs. (A) Immature monocyte-derived human DCs were stimulated with THP or LPS. Profiles with fine lines represent staining patterns with an isotype-matched control Ab, and profiles with bold lines represent staining with mAb of the indicated specificity. Data are representative of 5 independent experiments. Numbers indicate mean fluorescence intensity of specific Ab staining. (B) Immature human DCs were stimulated with different concentrations of THP or LPS. Cell-free supernatants were collected 18 hours after addition of THP or LPS and were analyzed by ELISA. Med, medium control. (C) Intracellular cytokines were stained in human DCs 18 hours after stimulation and then analyzed by FACS. Results are representative of 3 independent experiments. (D) Mouse RAW264.7 macrophages were exposed to THP, LPS, and CpG for the indicated time periods. Cell-free supernatants were analyzed for TNF-α by ELISA. Similar results were obtained in 3 other independent experiments.

Results
THP induces phenotypic maturation of human monocyte-derived DCs. We first sought to determine whether THP is able to induce maturation of immature DCs as reflected by phenotypic changes. DCs exposed to THP for 48 hours expressed the typical DC maturation markers CD80 and CD86, as well as the antigen-presenting molecules CD83 and CD25 (Figure 1A). Furthermore, the costimulatory molecules CD80 and CD86, as well as the antigen-presenting molecule HLA-DR, were upregulated. These phenotypic features exactly matched the DC maturation profile induced by LPS (Figure 1A).

In addition, maturation of DCs as reflected by IL-12p40 and TNF-α production was examined in THP- or LPS-stimulated DCs. THP was a potent inducer of proinflammatory cytokine secretion (Figure 1B) and production (Figure 1C). We also studied whether THP had effects on murine myeloid cells. THP induced cytokine production in spleenocytes, bone marrow-derived immature DCs, and the murine macrophage cell line RAW264.7 in a dose-dependent manner (Figure 1D and data not shown). These data indicate that THP potently stimulates myeloid immunocompetent cells leading to cytokine production and final maturation of immature monocyte-derived DCs.

LPS at concentrations as low as 50 pg/ml has been described to activate myelomonocytic cells (22). To exclude the possibility...
of THP with immature DCs led to a dramatic enhancement of their stimulatory capacity (Figure 3A). Further analysis of T cell cytokine production revealed that high levels of IL-2 and IFN-γ existed in allogeneic T cell cultures challenged with THP-treated DCs (Figure 3B). These data demonstrate a strong T cell responsiveness that occurs after activation of immature DCs by THP.

**THP induces activation of p38-MAPK, ERK-1/2, and Akt.** DC maturation has been shown to be associated with phosphorylation of distinct tyrosine kinases, including ERK, p38, and Akt (25). Addition of THP to human DCs (Figure 4A) or murine macrophages (Figure 4B) led to rapid phosphorylation of p38-MAPK and ERK within 15–30 minutes. Interestingly, we consistently found delayed phosphorylation of MEK1/2 (PD98059 and U0126) or p38 (SB203580) effectively blocked THP-induced TNF-α production in THP4 in THP-induced immune cell activation, human DCs were preincubated with the anti-TLR4 Ab, mAb H-TA5, and a significant impairment of cytokine production was observed (Figure 5C). These results indicate a critical role of TLR4 in THP-mediated immunostimulatory effects on DCs.

**Impaired cytokine production upon stimulation with THP in MyD88- and TLR4-null, but not in TLR2- and TLR9-null, mice.** To obtain direct evidence of TLR activation upon THP engagement, we isolated bone marrow–derived macrophages from MyD88 and TLR2, TLR4, and TLR9 KO mice as well as from WT mice. While THP potently stimulated TNF-α production in APCS obtained from WT, TLR2/−/−, and TLR9/−/− mice, cells from TLR4/−/− and MyD88/−/− mice were completely resistant to THP or LPS stimulation (Figure 6A). Importantly, myeloid cells from TLR4/−/− mice were functionally active, since they fully responded to the TLR2 agonist Pam3Cys (Figure 6, A and B).

To analyze cytokine production in vivo, WT and TLR4/−/− mice were challenged with intravenous administration of THP. One hour after THP or LPS injection, high levels of TNF-α were detected in WT mice (Figure 6C). In contrast, no detectable amounts...
of TNF-α were observed in TLR4−/− mice challenged with THP, indicating a complete unresponsiveness toward the immunostimulatory effects of the glycoprotein. Thus, the prominent proinflammatory cytokine induction by THP in vivo occurs by a TLR4-dependent mechanism.

THP-mediated Ab production in vivo is abrogated in TLR4−/− mice. Increased production of THP-specific autoantibodies is a consistent finding in several inflammatory disorders and infections of the urinary tract (13, 29, 30). Furthermore, THP has previously been shown to be a powerful autoantigen when rats, mice, or rabbits were challenged with autologous THP (31–33). We therefore were interested in the involvement of the TLR4-signaling pathway in the induction of an Ab response against THP. We detected a prominent IgG response in C57BL/6 mice within 7 days after intravenous THP delivery (Figure 6D). While WT mice displayed a typical Ab kinetic over a period of 35 days, TLR4−/− mice were dramatically impaired in their ability to produce specific Abs in response to THP challenge (Figure 6D). LPS was not able to induce any Ab response in both mouse strains (Figure 6D). These data show that TLR4 plays a pivotal role not only in THP-induced proinflammatory cytokine production, but also in the emergence of an anti–THP-directed immune response.

Discussion

DCs link the innate with the adaptive immune system by their ability to sense different microbial stimuli and conveying this information to lymphocytes. This process is accomplished by pathogen recognition and subsequent induction of the DC maturation program comprising increased surface expression of costimulatory molecules, cytokine production, and potent antigen-presenting function. In this study the unique property of the abundant urinary glycoprotein THP to activate professional APCs such as DCs is demonstrated to involve functional TLR4 signaling. Furthermore, THP-specific humoral immune responsiveness was found to be severely impaired in the absence of intact TLR4 signaling, indicating a failure to implement APC-driven specific immune cell activation.

Numerous clinical and experimental studies have indicated an involvement of THP in several forms of inflammatory kidney disease. While THP is normally expressed at the luminal surface of renal tubular epithelial cells and excreted into the urine, its aberrant presence was also detected at the basolateral surface and in interstitial infiltrates in several inflammatory kidney diseases (34–36). Earlier studies indicated a role of THP in the pathogenesis of interstitial nephritis, since intravenous challenge of animals with THP resulted in the induction of a tubulointerstitial inflammatory response and microscopic scarring localized to the distal nephron segments (31–34). Furthermore, cytotoxic T cells with specificity for THP and anti-THP Abs were present in affected animals. Ab responses to THP are a well-known phenomenon in patients with infections of the urinary tract such as interstitial cystitis (37, 38) and acute pyelonephritis (30, 39, 40), where THP has been discussed to be involved in kidney scarring leading to overt renal insufficiency (29, 41). Moreover, elevated autoantibody levels against THP could be involved in chronic pyelonephritis and subsequent renal damage (15, 16). Abnormal deposition of THP and ensuing inflammatory reactions have been consistently observed in cast nephropathy and urolithiasis (13, 16). In acute renal transplant rejection THP deposits were found to be surrounded by mononuclear cell infiltrates (42), similar to kidneys affected by immunoglobulin light chain deposition in patients with multiple myeloma (43). Despite the apparent participation of THP in a large variety of inflammatory kidney diseases, the underlying mechanisms that would explain how THP contributes to inflammatory reactions have largely remained obscure.

In the present study we clearly show that THP is able to induce maturation of immature DCs by a TLR4-dependent mechanism. Moreover, our study is in line with previous findings demonstrating that intravenous challenge with THP or autologous urine results in rapid induction of THP Abs. Remarkably, TLR4 is essential for the THP-specific Ab response in the present model as TLR4−/− mice were severely impaired in their THP-specific humoral immune responsiveness. In this respect, THP might be regarded as both adjuvant and antigen because it stimulates its own Ab production. Presumably, healthy mammals do not raise Abs against THP because the exclusive localization of THP at the luminal surface of tubular epithelial cells keeps the protein from the Ab-producing machinery. Segregation could be abolished in kidney diseases by loss of cell integrity or of luminal/basolateral tubular polarization. The physiological function of THP, therefore, could come from its ability to immediately activate innate immune responses, also recruiting components of the adaptive arm of the immune system. THP could thereby provide a critical danger sig.
nal to prevent host invasion of potentially harmful bacteria in case of local injury or increased epithelial permeability. While considered as a glycoprotein with direct antimicrobial effects, as has been suggested in recent studies employing THP–/– mice (20, 21), our data indicate a further role of THP as an endogenous activator of local immune responsiveness.

Various investigators have pointed to the problem of sufficiently high purity of potential immunostimulatory molecules acting through TLR. Therefore, it is of note that a number of data in the present as well as in previous studies (18, 44) confirmed that the results obtained with THP are not due to contaminating LPS. First, polymyxin B, which binds to lipid A and thereby blocks LPS responses, did not affect activation of both human and mouse APCs at all. Second, we found that HUVECs, which respond to very low amounts of LPS with TF production, were completely insensitive toward THP. Finally, the complete lack of response to THP in Tlr4–/– cells rule out possible contaminations with lipoproteins or lipopeptides. We cannot, however, completely eliminate the possibility that THP may act as a potentiator of subthreshold amounts of LPS or some other bacterial cell wall components that are tightly bound within the THP molecule and that might directly stimulate TLR4. Even in this case, however, THP could play a significant antibacterial role by amplifying potential danger signals derived from microbes entering the urinary tract and thereby inducing an appropriate antibacterial host response.

Recent studies have identified various sugar structures such as zymosan (7, 8), hyaluronic acid (10), or phospholipomannan (6) as effective activators of myeloid cells. In these studies an absolute requirement was demonstrated for the engagement of TLR2, TLR4, or both receptors for proper immune cell activation. Therefore, it is currently believed that bacterial recognition and subsequent immune cell activation might depend on both a functional TLR complex and a specific sugar-recognizing receptor supporting a model in which specific host responses are mediated by a combination of molecules (3). It was recently shown that zymosan activates immune cells only by engagement of both dextrin-1, its respective receptor, and TLR2 (7, 8). The highly complex glycomoity of THP, which consists of n-linked glycans of the polyanenasty-type sialylated, fucosylated, and sulphated sugar residues that are evolutionarily conserved across species (13), might similarly contain ligands for a sugar-recognition receptor. Therefore, further investigations will focus on the identification of the active moietry and a putative cell surface receptor for THP.

In conclusion, we demonstrate here that the abundant urinary glycoprotein THP is a strong activator of professional APCs, including DCs. Its immunostimulatory potential and its ability to induce an anti-TLR Ab response depends critically on TLR4 and its subsequent signaling pathway. We hypothesize that THP might serve as an endogenous activator of a molecular machinery typically associated with host responsiveness against bacterial infections. Similar data were recently reported for β-defensin 2, which is also produced by tubular epithelial cells. While similarly considered as peptide with direct antimicrobial activity, β-defensin 2 possesses DC stimulatory properties involving a TLR4-
dependent process (11). Our findings thus extend the understanding of THP’s function in antibacterial defense mechanisms and may have broad implications for the regulation of immune responses in the urinary tract.

Methods

**Media and reagents.** LPS (Escherichia coli 0111:B4) was purchased from Sigma-Aldrich Chemie GmbH. Human THP isolated from sterile urine from healthy individuals, purified by 3 repetitive cycles of precipitation in 0.58 M NaCl and centrifugation as described (45), was purchased from Accurate Chemical & Scientific Corp. Purity was assessed through a single homologous band at 92 kDa in SDS-PAGE. Mouse THP was purified from sterile urine from female C57BL/6 mice by precipitation in 0.58 M NaCl as described (46) or by dialysis against PBS using a 50-kDa Spectra/Por Biotech RC dialysis membrane from Spectrum Laboratories Inc. To further purify THP, the THP precipitation was diluted in sodium phosphate buffer, pH 6.3, to a concentration of 70 mM to induce THP gel formation and was incubated for 1 hour at room temperature. Afterward, the sample was ultracentrifuged at 109,000 g for 30 minutes at 10°C, and the pellet was dissolved in H2O and dialyzed against water (23). The pellet fraction contained the majority of THP as assessed by SDS-PAGE. The pellet fraction was further purified by bringing the solution to 140 mM NaCl and 250 mM phosphate buffer, pH 7.5, which induces gel formation. The THP sample was then added onto a column containing diatomaceous earth, washed with PBS, and eluted by addition of H2O as described (24). The MAPK inhibitors SB203580, PD98059, and UO126 and the NF-κB inhibitor SN50 were purchased from Calbiochem. Polymyxin B was from Sigma-Aldrich Chemie GmbH. Affi-Prep Polymyxin Support was from Bio-Rad Laboratories Inc.

All reagents, media, and buffers used in our assays were checked by Limulus amebocyte lysate assays (BioWhittaker Inc.) and contained less than 0.06 U/ml of endotoxin in accordance with the European Community standard of water injection. The TIRAP/Mal inhibitory peptide (28), consisting of a Drosophila antennapedia sequence positioned at the N-terminal end of TIRAP amino acids 138–145, was synthesized by Fmoc-chemistry. Tripalmitoyl cysteinyllipopeptide was purchased from EMD Microcollections. Mouse mAb against human TLR4 (HTA125) was from ebioscience. PE-labeled IL-12 and TNF-α mAbs were from BD Biosciences. RPMI-1640 (Invitrogen Corp.) supplemented with 2 mM L-glutamine, 100 μg/ml streptomycin, 100 U/ml penicillin, and 10% FCS (HyClone Laboratories Inc.) was used as culture medium. Recombinant human GM-CSF (rhGM-CSF) was obtained from Schering-Plough and rhIL-4 was from Strathmann Biotech GmbH.

Cell separation and preparation of human DCs. Human PBMCs were isolated by density-gradient centrifugation over endotoxin-free Lymphoprep (Nycomed AS). Cell-free supernatants were collected and analyzed by ELISA. Data are representative of 3 independent experiments. mDCs, monocyte-derived DCs. *Significantly different from the values for stimulated control; P < 0.05.
Pharma A/S). For monocyte enrichment, PBMCs were depleted of T cells by sheep erythrocyte rosetting. Resting T cells were isolated by sheep erythrocyte rosetting and subsequent lysis of remaining erythrocytes at 4°C.

For DC differentiation, enriched monocytes were cultured in 50 ng/ml rhGM-CSF and 10 ng/ml rHRL-4 for 5–7 days. DC activation was induced by THP or LPS addition for 48 hours.

**Mouse studies.** Female C57BL/6 mice were obtained from Harlan Winkelmann GmbH. Th2−/−, Th4−/−, Th9−/−, and MyD88−/− mice in a C57BL/6 background were housed under specific pathogen-free conditions. Mice were used at age 6–8 weeks. All animal experiments were approved by the veterinary magistrate (MA58/60) of Vienna, Austria. Bone marrow–derived macrophages were prepared by incubation of 10^7 bone marrow cells with 1 ml conditioned M-CSF medium. For in vivo studies, 50 μg THP or 50 ng LPS in 100 μl PBS were injected intravenously in the tail vein on days 0, 1, 2, and 7. Blood was taken on the indicated days, and Ab levels against THP were measured by ELISA. Briefly, 5 μg/ml THP or OVA were coated on MaxiSorp plates (Nunc A/S) overnight and serial dilutions of blood serum were applied. Specific Ab binding was proven using a peroxidase-conjugated F(ab′)2 fragment of a rabbit anti-mouse Ab provided by Jackson ImmunoResearch.

**Phenotypical characterization of DCs by FACS analysis.** For evaluation of surface marker expression, cells were incubated with FITC- or PE-conjugated mAb for 30 minutes at 4°C. For control, nonbinding isotype-matched FITC- and PE-conjugated mouse IgGs were used. Cells were analyzed on a FACScalibur flow cytometer (BD Biosciences). FITC-conjugated CD25 (2A3), anti–HLA-DR (L243), and anti-CD83 (HB15e), as well as PE-labeled Oligo(dT)20 and CD45, as well as PE-labeled anti-CD80 (L307.4) and anti-CD86 (IT2.2) mAb, were from BD Biosciences.

**Measurement of cytokine production and T cell proliferation.** For determination of TNF-α and IL-12p40, 5 × 10^5 DCs were stimulated with THP (10 μg/ml), LPS (100 ng/ml), or CpG (10 μM) in 24-well plates (final volume 1 ml). Cell-free supernatants were harvested 48 hours after addition of the bacterial stimulus. Cytokines were measured by sandwich ELISA using matched-pair Abs. Capture as well as detection Abs against human IL-12p40 were obtained from R&D Systems Inc. Abs against human TNF-α were from BD Biosciences. Standards consisted of human recombinant material from R&D Systems Inc. Abs were set up in duplicates and were performed according to the recommendations of the manufacturers. The lower limit of detection was 20 pg/ml for all cytokines.

**Cellular signaling and EMSA.** Cells were lysed in a buffer containing 0.5% Nonidet P-40, 20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM MgCl_2, 1 mM EGTA, and 2 mM dithiothreitol. Lysates were clarified by centrifugation (12,000 g for 20 seconds) and lysates on ice for 30 minutes in TBS, pH 7.4, containing 1% NP-40 (Pierce Biotechnology Inc.), phosphatase (1 mM sodium orthovanadate, 10 mM NaF, 5 mM sodium pyrophosphate, 25 mM [γ-glycerophosphate, 5 mM EDTA), and protease inhibitors. Nuclei were removed by short centrifugation; supernatants are referred to as whole-cell lysates. Proteins were separated using SDS-PAGE and were blotted onto nitrocellulose membranes (Hybond ECL; Amersham Biosciences). Abs against IRAK-1 (Santa Cruz Biotechnology Inc.), Akt (BioVision Inc.), and ERK-2, p38, α-actin (Santa Cruz Biotechnology Inc.) were used to detect the respective antigens. Protein phosphorylation was assessed using Abs directed against phosphorylated isoforms of Akt (BioVision Inc.), ERK-1/2 (Santa Cruz Biotechnology Inc.), and p38 (Cell Signaling Technology Inc.). Peroxidase-labeled secondary Abs (Bio-Rad Laboratories Inc.) were used to detect primary Ab binding. Chemiluminescence generated from enhanced chemiluminescence substrate (Roche Diagnostics GmbH) was detected on a Lumi-Imager (Roche Diagnostics GmbH) (48).

**Clotting assay determination of TF activity.** HUVECs were seeded in 6-well plates at 80–90% confluence and grown overnight. Cells were scraped from the plates and analyzed for TF activity as described (49). HUVECs were left untreated or treated with 200 U/ml IFN-γ (R&D Systems Inc.) for 2 hours and then stimulated with LPS or THP at the indicated concentrations for 6 hours. The cells were washed twice and scraped in 1 ml clotting buffer (12 mM sodium acetate, 7 mM diethylbarbiturate, and 130 mM sodium chloride; pH 7.4); 100 μl of resuspended cells were mixed with 100 μl of citrated plasma, and clotting times were measured after recalcification with 100 μl of 20 mM CaCl_2 solution at 37°C. TF equivalents were determined using a standard curve obtained from rabbit brain thromboplastin.

**EMSA.** Nuclear extracts from DCs were prepared as described (50, 51). Oligonucleotides resembling the consensus binding site for NF-κB were purchased from Santa Cruz Biotechnology Inc. This work was supported in part by grants (P14874-B06, to G.J. Zlabinger, P16788-B13, to T.M. Stulnig) from the Fonds zur För- derung der Wissenschaftlichen Forschung, Österreich, as well as by grants from the Center of Molecular Medicine (CeMM), a basic research institute within the companies of the Austrian Academy of Sciences (to T.M. Stulnig). Moreover, we are grateful to Wolfgang Zauner for synthesis of the TIRAP/Mal inhibitory peptide, and to Bianca Weissenhorn, Alessandra Mathe, and Margarethe Merio for excellent technical assistance.

Received for publication July 14, 2004, and accepted in revised form November 10, 2004.
Address correspondence to: Gerhard J. Zlabinger, Institute of Immunology, Medical University Vienna, Borschkeggasse 8a, A-1090 Vienna, Austria. Phone: 431-4277-64971; Fax: 431-4277-64972; E-mail: Gerhard.Zlabinger@meduniwien.ac.at.

G. Staffler’s and U. Ahsen’s present address is: Bioverits AG, Campus Vienna Biocenter 6, Vienna, Austria.

M.D. Saemann and T. Weichhart contributed equally to this work.


